Zentalis Pharmaceuticals, Inc.

About Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, with a mission to improve patient lives through innovative oncology therapies.

Products & Services

Azenosertib:A lead compound being studied as both monotherapy and in combination therapies across multiple tumor types, including PROC, uterine serous carcinoma, and ovarian cancer, with ongoing clinical trials such as DENALI, TETON, and others. It has received FDA Fast Track Designation for certain indications.

Specialties

Oncology therapies Small molecule therapeutics Integrated discovery engine for cancer treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 250000000 MR: - FA: approximately $250.0 million FAN: 250000000	D: 2023-06-15 FD: 2023-06-15	5 investors

Public Offering Latest

2023-06-15

$250.0M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Julie Eastland

Chief Executive Officer, President and Director

I

Ingmar Bruns

Chief Medical Officer

W

Wendy Chang

Chief People Officer

J

James Bucher

Chief Legal Officer and Corporate Secretary

H

Haibo Wang

Chief Business Officer

R

Robert DiVasto

Senior Vice President, Technical Operations

View 17 more team members with Pro

Unlock Full Team Directory

Recent News